APUS vs BILL · $2.4M cap vs rev $1.46B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Bill Com Holdings Inc (BILL) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Bill Com Holdings Inc (BILL) is a software - application company listed on US.
APUS does not have a complete income-statement cache yet.
Latest reported BILL revenue for 2025-06-30 was $1.46B. Net income was $23.8M. Revenue was up 13.4% from 2024-06-30 to 2025-06-30. BILL currently screens at market cap $4.78B.
APUS currently screens at market cap $2.4M. BILL currently screens at market cap $4.78B.
Not investment advice. Open the APUS and BILL stock pages for the full models.
Not investment advice.